TheraRadar
← Back
Data updated: Jun 28, 2026

ALMIRALL

Specialty
DermatologyImmunologyRespiratory Execution: Excellent

ALMIRALL is a specialty pharmaceutical company focused on Dermatology, Immunology, Respiratory. Key products include SEYSARA.

1969
Since
9
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
7 Small Molecules

FDA Novel Drug Designations

(2018-2020)
2 Novel 1 First-in-Class
See 2 novel approvals →
2020 KLISYRI (TIRBANIBULIN) First-in-Class
2018 SEYSARA (SARECYCLINE HYDROCHLORIDE)

ALMIRALL at a Glance

  • Strong track record with 81% execution quality across 54 trials
  • Fast trial execution (11 months median completion)

ALMIRALL's Key Drugs

ALMIRALL's core commercial portfolio centers on KLISYRI, SEYSARA, spanning Dermatology and Immunology — its most strategically important drugs approved in the last 15 years.

KLISYRI
Dermatology

Actinic Keratosis

Microtubules Approved 2020
SEYSARA
Dermatology

Acne Vulgaris

Approved 2018

ALMIRALL's Recent FDA Approvals

New NDA/BLA approvals for ALMIRALL over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

ALMIRALL's Therapeutic Areas

ALMIRALL's approved drugs and pipeline span 5 therapeutic areas, led by Dermatology and Immunology, across 0 biologic and 7 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Dermatology 64%
6 drugs Phase 3: 10 Phase 2: 4 Phase 1: 1
Immunology 26%
2 drugs Phase 3: 1 Phase 2: 6 Phase 1: 6
Respiratory 7%
0 drugs Phase 3: 2 Phase 1: 1
Neurology 3%
0 drugs Phase 3: 1
Infectious Disease 1%
0 drugs Phase 1: 1

ALMIRALL Pipeline Snapshot

ALMIRALL has 33 active clinical programs from ClinicalTrials.gov — 14 Phase 3, 10 Phase 2 and 9 Phase 1.

14
Phase 3
10
Phase 2
9
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • KLISYRI leads revenue
  • • 2 key drugs tracked
View revenue breakdown →

Trial Catalysts

  • • Dermatology pipeline focus
  • • Phase 3 readout tracking
View full pipeline →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis
View patent timeline →

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Compare with competitor →

Execution Intelligence

  • • Phase 3: 17/21 completed
  • • Speed: 11 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges